Abstract: This disclosure relates to a motor vehicle, and in particular a vehicle body structure for a motor vehicle, with a reinforcement structure including an additively manufactured bracket. An example motor vehicle has a vehicle body structure including a reinforcement structure. The reinforcement structure includes a tube and a bracket additively manufactured to the tube.

Abstract: This disclosure relates to a motor vehicle, and in particular a vehicle body structure for a motor vehicle, with a reinforcement structure including an additively manufactured bracket. An example motor vehicle has a vehicle body structure including a reinforcement structure. The reinforcement structure includes a tube and a bracket additively manufactured to the tube.

Abstract: The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating tablets containing (1S,2S,3R,5S)-3-[7-{[1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5 5-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient. Blister packs suitable for use with the rapidly disintegrating oral dosage form are also disclosed.

Abstract: A method for differentiation of normal myocardium from diffuse disease using T mapping includes acquiring one or more images of a patient by an imaging apparatus, generating a T1 map from the one or more images, defining a region of interest within the one or more images, determining the average T1 value within the region of interest, comparing the average T1 value within the region of interest to a cut-off T1 value, and determining a diagnosis of the region of interest from the comparison.

Abstract: The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating tablets containing (1S ,2S ,3R,5S)-3-[7-{[1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-55-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient. Blister packs suitable for use with the rapidly disintegrating oral dosage form are also disclosed.

Abstract: The invention relates to determining a context of a system so that the system can be controlled or the context information be used in the system. The context of a system is described with tags or words that characterize e.g. the state of the system, the surroundings of the system and the state of the user. These tags are determined at multiple time instances. The tags are collected over a first time span and a second time span, and the two (or more) sets of tags are used to determine the context of the system. If the determination using the two sets gives a different result, that is, there is a large distance between the two derived contexts, it is determined that a change in context has occurred. Detecting the change in context can be used to control the system, e.g. by changing the applications presented to the user on the user interface, or by changing the state and/or priority of applications.

Abstract: A medical imaging system (5) includes a data store (12), a clustering module (22), and a display device (32). The data store (12) includes a first imaging data set and a second imaging data set, each data set created with the same imaging device (10) and the same measured value. The measured value of a first and a second tissue type overlap in the first imaging data set. The measured value of the second and a third tissue type overlap in the second data set. The data sets are co-registered, and an external event changes the measured value of the second data set. The clustering module (22) classifies the tissue type based on a fuzzy clustering of the measured value of the first data set and the measured value of the second data set for each location. The display device (32) displays a medical image which contrasts each classified tissue type.

Abstract: The present invention relates to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds contain a turn-inducing group between the pair of cross-metathesisable groups to facilitate the cross-metathesis.

Abstract: A medical imaging system (5) includes a data store (12), a clustering module (22), and a display device (32). The data store (12) includes a first imaging data set and a second imaging data set, each data set created with the same imaging device (10) and the same measured value. The measured value of a first and a second tissue type overlap in the first imaging data set. The measured value of the second and a third tissue type overlap in the second data set. The data sets are co-registered, and an external event changes the measured value of the second data set. The clustering module (22) classifies the tissue type based on a fuzzy clustering of the measured value of the first data set and the measured value of the second data set for each location. The display device (32) displays a medical image which contrasts each classified tissue type.

Abstract: The invention relates to determining a context of a system so that the system can be controlled or the context information be used in the system. The context of a system is described with tags or words that characterize e.g. the state of the system, the surroundings of the system and the state of the user. These tags are determined at multiple time instances. The tags are collected over a first time span and a second time span, and the two (or more) sets of tags are used to determine the context of the system. If the determination using the two sets gives a different result, that is, there is a large distance between the two derived contexts, it is determined that a change in context has occurred. Detecting the change in context can be used to control the system, e.g. by changing the applications presented to the user on the user interface, or by changing the state and/or priority of applications.

Abstract: A method for differentiation of normal myocardium from diffuse disease using T mapping includes acquiring one or more images of a patient by an imaging apparatus, generating a T1 map from the one or more images, defining a region of interest within the one or more images, determining the average T1 value within the region of interest, comparing the average T1 value within the region of interest to a cut-off T1 value, and determining a diagnosis of the region of interest from the comparison.

Abstract: The present invention related to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds containing a turn-induced group between the pair of cross metathesisable groups to facilitate the cross-metathesis.

Abstract: The invention provides a method of preparing a crosslinked polymer, which method comprises polymerising branched polyunsaturated monomers by a metathesis polymerisation reaction, wherein the branched polyunsaturated monomers contain acyclic ethylenically unsaturated groups that are capable of undergoing polymerization by a metathesis reaction such that the metathesis polymerisation produces a crosslinked polymer and substantially no non-volatile ethylenically unsaturated by-products.

Abstract: The invention provides a method of preparing a crosslinked polymer, which method comprises polymerising branched polyunsaturated monomers by a metathesis polymerisation reaction, wherein the branched polyunsaturated monomers contain acyclic ethylenically unsaturated groups that are capable of undergoing polymerization by a metathesis reaction such that the metathesis polymerisation produces a crosslinked polymer and substantially no non-volatile ethylenically unsaturated by-products.

Abstract: The present invention relates to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds contain a turn-inducing group between the pair of cross-metathesisable groups to facilitate the cross-metathesis.

Abstract: The present invention relates to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds contain a turn-inducing group between the pair of cross-metathesisable groups to facilitate the cross-metathesis.

Abstract: The invention provides a method of preparing a crosslinked polymer, which method comprises polymerising branched polyunsaturated monomers by a metathesis polymerisation reaction, wherein the branched polyunsaturated monomers contain acyclic ethylenically unsaturated groups that are capable of undergoing polymerization by a metathesis reaction such that the metathesis polymerisation produces a crosslinked polymer and substantially no non-volatile ethylenically unsaturated by-products.

Abstract: A medicament or device for tissue regeneration, for example bone and/or cartilage tissue, in which the medicament or device comprises a BMP binding protein.

Abstract: The present invention provides a novel process for making compounds of formula 2a or 2b or pharmaceutically acceptable salts thereof, ##STR1## wherein R.sub.1 is selected from the group consisting of phenyl and phenyl substituted with at least one group selected from NO.sub.2 and halogen;R.sub.2 is H;R.sub.3 is selected from the group consisting of C.sub.1-4 alkyl, phenyl, and benzyl; and,R.sub.4 is selected from the group consisting of H and halogen;which comprises the steps of:a) oxidizing a racemate of formula 2 or a salt thereof to form a dehydro-compound of formula 3, ##STR2## wherein R.sub.5 is selected from the group consisting of H, CH.sub.3, benzyl, C.sub.2-8 acyl Na, Li and K; and,b) asymmetrically hydrogenating a compound of formula 3 in the presence of a chiral phosphine catalyst to form a compound of formula 2a or 2b.

Abstract: The present invention provides a novel process for making compounds of formula 2a or 2b or pharmaceutically acceptable salts thereof, ##STR1## wherein R1 is selected from the group consisting of phenyl and phenyl substituted with at least one group selected from NO.sub.2 and halogen;R.sub.2 is H;R.sub.3 is selected from the group consisting of C.sub.1-4 alkyl, phenyl, and benzyl; and,R.sub.4 is selected from the group consisting of H and halogen;which comprises the steps of:a) oxidizing a racemate of formula 2 or a salt thereof to form a dehydro-compound of formula 3, ##STR2## wherein R.sub.5 is selected from the group consisting of H, CH.sub.3, benzyl, C.sub.2-8 acyl Na, Li and K; and,b) asymmetrically hydrogenating a compound of formula 3 in the presence of a chiral phosphine catalyst to form a compound of formula 2a or 2b.